Back to today’s briefing

Story perspectives

Monoclonal Antibodies: New Hope for Allergy Sufferers

4/15/2025

24 3

Summary

Story summary

Monoclonal antibodies, such as omalizumab (Xolair), are emerging as a game-changer for seasonal allergy sufferers, providing relief with just one injection before symptoms strike. Unlike standard antihistamines, they tackle multiple allergies at once. Yet, the journey to FDA approval and the burden of high costs for insurance coverage pose significant hurdles for hopeful patients.

1 of 1

Story summary

Monoclonal antibodies, such as omalizumab (Xolair), are emerging as a game-changer for seasonal allergy sufferers, providing relief with just one injection before symptoms strike. Unlike standard antihistamines, they tackle multiple allergies at once. Yet, the journey to FDA approval and the burden of high costs for insurance coverage pose significant hurdles for hopeful patients.